Table 4 Multivariate survival analysis of intermediate- and high-risk patients

Middle risk(N = 204)

 Primary tumor site

  Others vs. stomach

1.77(1.41–2.18)

 < 0.001

–

–

 Ki-67 index

  > 5 vs. ≤ 5

1.22(1.11–1.39)

0.008

 TKI therapy

  Irregular vs. regular

–

–

1.95(1.31–2.49)

 < 0.001

High risk(N = 331)

 Primary tumor site

 < 0.001

 < 0.001

  DU + SM vs. stomach

1.43(1.18–1.67)

0.008

1.33(1.07–1.59)

 < 0.001

  Others vs. stomach

1.79(1.28–2.19)

 < 0.001

1.55(1.19–2.00)

 < 0.001

 Tumor size (cm)

 < 0.001

 < 0.001

  5–10 vs. ≤ 5

1.12(1.04–1.31)

0.023

1.02(1.01–1.21)

0.037

  > 10 vs. ≤ 5

3.22(2.39–5.48)

 < 0.001

2.63(2.09–4.03)

 < 0.001

 Ki-67 Index(%)

 < 0.001

 < 0.001

  5–10 vs. ≤ 5

1.11(1.09–1.34)

0.018

1.38(0.94–2.06)

0.061

  > 10 vs. ≤ 5

2.49(1.89–3.27)

 < 0.001

2.74(2.00–3.76)

 < 0.001

 Mitotic rate

  > 10/50 vs. ≤ 10/50

1.33(0.59–2.44)

0.231

1.88(1.31–2.76)

 < 0.001

 Surgery

 < 0.001

0.331

  Local excision vs. contained DTE

1.14(1.03–1.27)

0.019

1.55(0.71–3.16)

0.514

  Local excision vs. extensive

2.97(2.01–4.09)

 < 0.001

1.99(0.97–2.76)

0.089

 TKI therapy

  Irregular vs. regular

2.71(2.09–3.29)

 < 0.001

1.89(1.45–3.12)

 < 0.001

Very high risk(N = 122)

 TKI therapy

  Over 3 years vs. 3 years

0.49(0.31–1.02)

0.061

0.43(0.15–0.66)

 < 0.001